The BalancedInvestor Club

BGM Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-0.290.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$60.4MMicro cap

Valuation

Forward P/E
—
PEG ratio
—
P/B
0.33
P/S (TTM)
0.22
EV/EBITDA
-2.48

Profitability & growth

ROE (TTM)
-16.5%
Operating margin
-15.6%
Revenue growth YoY
13.9%
Dividend yield
—
Beta
1.46
Last earnings
Jul 24, 2025 · Estimate $0.00 · Reported $-0.03
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Qilian International Holding Group Limited

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company is headquartered in Jiuquan, the People's Republic of China.

Classification

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
NO. 152 HONGLIANG EAST 1ST STREET, CHENGDU, CHINA
Fiscal year end
September
Latest quarter
Mar 31, 2025
Market cap$60.4M
Shares outstanding$180.6M
52W high$17.17
52W low$0.27

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer